Altimmune (ALT) Amortization of Deferred Charges (2010 - 2026)

Altimmune's (ALT) quarterly Amortization of Deferred Charges came in at $218000.0 in Q1 2026, up 13.54% on a QoQ basis from $192000.0 in Q4 2025.

Altimmune (ALT) Amortization of Deferred Charges (2010 - 2026) Analysis & Trends

Altimmune (ALT) has 5 years of Amortization of Deferred Charges data on file, last reported at $218000.0 in Q1 2026.

On a quarterly basis, Amortization of Deferred Charges changed N/A year-over-year to $218000.0 in Q1 2026; TTM through Mar 2026 was $583587.0, a N/A change from a year earlier, with the FY2025 full-year figure at $363000.0, changed N/A from the prior year.
Amortization of Deferred Charges for Q1 2026 stood at $218000.0, up from $192000.0 in the prior quarter.
Over the last five years, Amortization of Deferred Charges for ALT reached as high as $218000.0 in Q1 2026 and fell as low as $113000.0 in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn
4	NuCana	279.75 Bn	279.75 Bn	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-
10	Altimmune	7.96 Mn	7.96 Mn	-

Download Data